Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma

Abstract

The combination of DB with the checkpoint inhibitor nivolumab led to complete and a very good partial remission in two patients with relapsed/refractory NB. Prospective trials are warranted to clarify the role of this novel approach in a larger number of patients.